资讯

Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 Filing ...

Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds

SAN DIEGO, CA / ACCESS Newswire / September 11, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the “Company” or ...